key: cord-0944398-ns9aan9l authors: Fattizzo, Bruno; Giannotta, Juri A.; Cecchi, Nicola; Barcellini, Wilma title: SARS‐CoV‐2 vaccination in patients with autoimmune cytopenias: The experience of a reference center date: 2021-09-16 journal: Am J Hematol DOI: 10.1002/ajh.26345 sha: 9af62b04797b3b86cbbc2eec1422a6b2b9a83d70 doc_id: 944398 cord_uid: ns9aan9l nan Additional supporting information may be found in the online version of the article at the publisher's website. Adenovirus based vaccine AstraZeneca) have been described, 3 Figure S1 ). Regarding AIHA, four elderly patients experienced a clinically sig- Adverse events, N(%) -7 (12.5) 8 (14) Fever, N(%) Other, N(%) Delta% change, median (range) -À20 (À29; À12) À20 (À28; À7) Adverse events, N(%) -1 (14) 1 (14) Fever, N(%) -0 1 (14) Pain, N(%) increasing eltrombopag dose and with the addition of prednisone In conclusion, our study along with the evidence above, underlines that post-vaccine AIC flares are manageable and that the benefits of vaccination greatly outweigh the risks. The hematologic monitoring adopted in our survey (1 week before, 1 week after the first and the second dose) appears appropriate to promptly intercept and manage AIC reactivations. We also avoided modifications of the ongoing AIC treatment in the 2-3 weeks preceding vaccine to prevent AIC exacerbations unrelated to vaccination. One of the main concerns is whether to administer the second dose after an AIC flare following the first one. Apart from patients' refusal, the second dose should be carefully weighed, and may be feasible upon close monitoring of blood counts and therapy adjustment. All these measures will ensure a safe vaccination campaign in this patient population. No funding sources to declare. The authors declare that they have no conflict of interest. B.F., J.A.G., N.C., and W.B. designed the study, collected data and wrote the paper. Further data will be available upon request to the corresponding author. Bruno Fattizzo 1,2 , Juri A. Giannotta 1 , Nicola Cecchi 1,2 , Commentary: SARS-CoV-2 vaccines and cancer patients Vaccinations in CLL: implications for COVID-19 Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies Seroconversion rates following COVID-19 vaccination among patients with cancer MMR vaccine and idiopathic thrombocytopaenic purpura Drug induced immune thrombocytopaenia: results from the Berlin case-control surveillance study Autoimmune-and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination Acute immune thrombocytopenia (ITP) following COVID-19 vaccination in a patient with previously stable ITP A case of immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination COVID-19 vaccination associated severe immune thrombocytopenia Newly diagnosed idiopathic thrombocytopenia post COVID-19 vaccine administration Exacerbation of immune thrombocytopenia following COVID-19 vaccination Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination Severe, refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccine Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the vaccine adverse event reporting system (VAERS) A case of severe autoimmune hemolytic anemia after a receipt of a first dose of SARS-CoV-2 vaccine A case of autoimmune hemolytic Anemia following COVID-19 messenger ribonucleic acid vaccination Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies